University of Haifa   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Haifa Israel (1963)

Organization Overview

First Clinical Trial
2005
NCT00271791
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Carmal Medical Center, Haifa, Israel | Carmel Hospital | Carmel Hospital,Haifa | Carmel Medical Center, Haifa | Carmel Medical Center, Haifa, Israel | CARMEL MEDICAL CENTER - HAIFA -ISRAEL | Clinical Pharmacology Unit, Carmel Medical Center, Haifa | Department of Physical Therapy, University of Haifa | ENT Department, Carmel Medical Center, Haifa | Haifa University | Haifa University, Israel | Multiple Sclerosis Center Carmel Medical Center | Nursing School, University of Haifa | Prof. Simone Shamay-Tsoory, University of Haifa | Prof. Yoram Yovell | Sara Rosenblum | University of Haifa | University of Haifa, Institute for the Study of Affective Neuroscience

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Transitional Cell (Phase 1)

Congenital Abnormalities (Phase 4)

Crohn Disease (Phase 4)

Depression (Phase 3)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Guillain-Barre Syndrome (Phase 2)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 4)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Lymphoma (Phase 2)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Neuritis (Phase 2)

Ovarian Neoplasms (Phase 2)

Peritonitis (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Schizophrenia (Phase 2)

Sclerosis (Phase 4)

Suicidal Ideation (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Vestibular Diseases (Phase 2)

Vestibular Neuronitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 41